Medicine & Life Sciences
Neoplasms
100%
pembrolizumab
70%
Clinical Trials, Phase I
42%
Mutation
40%
Safety
35%
Bevacizumab
34%
selinexor
31%
Therapeutics
31%
Clinical Trials
29%
Survival
25%
Vascular Endothelial Growth Factor A
24%
Progression-Free Survival
23%
Maximum Tolerated Dose
20%
temsirolimus
19%
pazopanib
19%
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
19%
Cetuximab
18%
Everolimus
17%
Fatigue
17%
Sarcoma
16%
Response Evaluation Criteria in Solid Tumors
16%
Cell-Free Nucleic Acids
16%
Breast Neoplasms
16%
Non-Small Cell Lung Carcinoma
15%
Pharmacokinetics
15%
Immunotherapy
15%
Colorectal Neoplasms
14%
Crizotinib
13%
Carboplatin
13%
Erlotinib Hydrochloride
12%
Mitogen-Activated Protein Kinase Kinases
12%
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
11%
Carcinoma
11%
Paclitaxel
11%
Vorinostat
11%
High-Throughput Nucleotide Sequencing
11%
Vemurafenib
11%
Diarrhea
10%
Ligands
10%
Phosphatidylinositol 3-Kinases
10%
Thrombocytopenia
10%
Nausea
10%
Precision Medicine
10%
Oxaliplatin
10%
Lenalidomide
10%
Investigational Therapies
10%
Melanoma
9%
Squamous Cell Carcinoma
9%
MK 2206
9%
SOR-C13
9%